This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Archive


ITM announces successful fundraising of 20 million EUR

Clinical development of Targeted Radionuclide Therapies to get major boost Investment will support growth initiatives of the company

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced that it has raised 20 million EUR in equity from Medtech Focused Family Office.

ITM plans to use the funds for further development of its promising, proprietary pipeline of Targeted Radionuclide Therapies and to bring its innovative therapeutic and diagnostic products faster to the market. The investment will also ensure the continuing growth of the company.

“We are very pleased to have completed this fundraising which will help us to give our radiopharmaceutical products in clinical development a major boost”, said Steffen Schuster, Chief Executive Officer of ITM Group. “We thank our new investor for its confidence in ITMs groundbreaking role in setting new global standards in Precision Oncology and in bringing real added value to patients.”

About ITM
ITM Isotope Technologies Munich AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radiopharmaceuticals and radionuclides. Since its foundation in 2004, ITM and its subsidiaries have established the GMP manufacturing and a robust global supply network of a novel, first-in- class medical radionuclide and -generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM has developed a proprietary portfolio and growing pipeline of targeting molecules and therapies in various stages of clinical development addressing a range of cancers such as neuroendocrine-, prostate- and skin cancers as well as bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality-of-life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.